Q-Line Biotech NSE SME IPO review

  • The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
  • It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
  • As the company has no listed peers, it is trying to extract fancy price for its IPO.
  • Based on its overall financial data, the issue appears fully priced.
  • Well-informed investors may park moderate funds for long term.
Dilip Davda

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges. 

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies. 

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Q-Line Biotech IPO

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share.  The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes. 

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM group’s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, company’s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr. 

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained. 

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended Revenue Expense PAT Assets
2023 ₹184.81 ₹154.97 ₹32.10 ₹251.58
2024 ₹206.45 ₹175.85 ₹34.44 ₹339.25
2025 ₹322.58 ₹261.43 ₹28.13 ₹455.49
Dec 2025 ₹236.50 ₹186.96 ₹38.69 ₹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects. 

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company Face Value (₹) EPS basic (₹)Ā  EPS Diluted (₹) RONW (%) P/E Ratio NAV (₹)
Powerica Limited 5 15.26Ā  15.26 15.37 %Ā  24.45 99.76
Listed Peers
Cummins India Limited 2 72.15Ā  72.15 26.45% 64.13Ā  272.78
Kirloskar Oil Engines Limited 2 33.71 33.60 15.85% 43.24 212.60
NTPC Green Energy Limited 10 0.67 0.67 2.58% 129.40 21.88
Acme Solar Holdings Limited 2 4.55 4.53 5.59% 50.74Ā  74.54
Adani Green Energy Limited 10 8.37 8.37 11.90%Ā  101.53Ā  76.62
Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion
Q-Line Biotech IPO FAQs
1. What is Q-Line Biotech IPO? āŒ„
Q-Line Biotech IPO is SME IPO. The company is going to raise ₹214 Crores via IPO. The issue is priced at ₹326 to ₹343 per equity share. The IPO is to be listed on NSE SME.
2. When Q-Line Biotech IPO will open for subscription? āŒ„
The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.
3. What is Q-Line Biotech IPO Investors Portion? āŒ„
The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.
4. How to Apply the Q-Line Biotech IPO? āŒ„
You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.
5. What is Q-Line Biotech IPO Issue Size? āŒ„
Q-Line Biotech IPO issue size is ₹214 crores.
6. What is Q-Line Biotech IPO Price Band? āŒ„
Q-Line Biotech IPO Price Band is ₹326 to ₹343.
7. What is Q-Line Biotech IPO Lot Size? āŒ„
The minimum bid is 800 Shares with ₹2,74,400 amount.
8. What is the Q-Line Biotech IPO Allotment Date? āŒ„
Q-Line Biotech IPO allotment date is May 26,2026.
9. What is the Q-Line Biotech IPO Listing Date? āŒ„
Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

Bansal Wire IPO Date, Review, Price, Allotment Details

Bansal Wire IPO Details: Bansal Wire IPO date is fixed, the IPO is to hit the market on July 3, 2024 and will close on July 5, 2024. Bansal Wire IPO to raise around ₹745 crores via IPO that comprises fresh issue of ₹745 crores and offer for sale up to 29,101,562 equity shares of ₹5 each. The retail quota is 35%, QIB is 50%, and HNI is 15%.

Bansal Wire IPO

Bansal Wire is the largest stainless steel wire manufacturing company and the second largest steel wire manufacturing company by volume in India with a production of 72,176 MTPA and 206,466 MTPA, respectively, in Fiscal 2023, representing 20% and approximately 4% market share, respectively. (Source: CRISIL Report) The Company was incorporated in the year 1985 and since incorporation, they have consistently delivered quality products, creating a niche identity in the steel wire industry. With a legacy of 38 years, they take pride in their diversified portfolio, catering to a wide range of sectors such as automotive, general engineering, infrastructure, hardware, consumer durables, power and transmission, agriculture, and auto replacement.


They are an established player in the steel wire manufacturing business on account of the following:

  • They manufacture over 3,000 stock-keeping units (SKUs), the highest amongst all steel wire manufacturers in India with sizes ranging from as thin as 0.04 mm to as thick as 15.65 mm;
  • With a well-diversified base of more than 5,000 customers spanning various sectors, they have established a robust network that contributes to their sustained growth;
  • As part of their de-risking strategy, no single customer accounts for more than 5% of their sales, and no individual sector or segment constitutes more than 25% of their sales, ensuring a balanced and resilient business model;
  • They operate on a “Cost Plus model”, with a clear focus on staying immune to commodity price fluctuations;
  • Their Promoters have been in this steel wire manufacturing business since 1938, having experience for three generations;
  • They have a pan-India presence and their reach extends to more than 50 countries through product exports, solidifying their position as a key player in the international market;
  • They are currently operating from their four existing manufacturing facilities and will be setting up the largest single-location manufacturing facility of steel wire in Dadri, India, and will be amongst the largest capacities in Asia;
  • Their product mix and plant capabilities allow them to switch or add production lines from one sector to another based on industry demands; and
  • With a long-standing track record of generating operating profits, they have demonstrated their ability to navigate challenges and maintain a successful and sustainable business.

They operate in three broad segments, i.e., high carbon steel wire, mild steel wire (low carbon steel wire), and stainless steel wire and they will be also adding a new segment of specialty wires through their upcoming plant in Dadri, which will help us to grow and expand their market presence in upcoming fiscals.


Objects of the Issue

  • Repayment or prepayment of all or a portion of certain outstanding borrowings availed by our Company and our Subsidiary;
  • Funding the working capital requirements of the company
  • General corporate purposes.

Bansal Wire IPO Review (Apply or Not)

  • May Apply

Brokerage Firm IPO Review

  • Swastika Investmart: May Apply

Bansal Wire IPO Date & Price Band Details

IPO Open:July 3, 2024
IPO Close:July 5, 2024
IPO Size:Approx ₹745 Crores, 29,101,562 Equity Share
Fresh Issue:Approx ₹745 Crores, 29,101,562 Equity Share
Face Value:₹5 Per Equity Share
IPO Price Band:₹243 to ₹256 Per Share
IPO Listing on:BSE & NSE
Retail Quota:35%
QIB Quota:50%
 NII Quota:15%
Discount:N/A
DRHP Draft Prospectus:Click Here
RHP Draft Prospectus:Click Here
Anchor Investors List:Click Here

Bansal Wire IPO Market Lot

The Bansal Wire IPO minimum market lot is 58 shares with ₹14,848 application amount. The retail investors can apply up-to 13 lots with 754 shares or ₹193,024 amount.

ApplicationLot SizeSharesAmount
Retail Minimum158₹14,848
Retail Maximum13754₹193,024
S-HNI Minimum14812₹207,872
B-HNI Minimum683944₹1,009,664

Bansal Wire IPO Allotment & Listing Dates

The Bansal Wire IPO date is July 3 and the close date is July 5. The Bansal Wire IPO allotment will be finalized on July 8 and the IPO listing on July 10.

IPO Open Date:July 3, 2024
IPO Close Date:July 5, 2024
Basis of Allotment:July 8, 2024
Refunds:July 9, 2024
Credit to Demat Account:July 9, 2024
IPO Listing Date:July 10, 2024

You can check IPO subscription status and IPO allotment status on their respective pages.

Bansal Wire IPO Form

How to apply for the Bansal Wire IPO? You can apply for Bansal Wire IPO via ASBA available in your bank account. Just go to the online bank login and apply via your bank account by selecting the Bansal Wire IPO in the Invest section. The other option is you can apply for Bansal Wire IPO via IPO forms downloaded via NSE and BSE. Check out the Bansal Wire forms – Click BSE Forms & NSE Forms blank IPO forms download, fill, and submit in your bank or with your broker.


Bansal Wire Company Financial Report

  ₹ in Crores
YearRevenueExpensePAT
2021₹1480.42₹1424.11₹40.47
2022₹2205.07₹2126.94₹57.29
2023₹2422.57₹2341.02₹59.93
Sept 2023₹1154.03₹1105.62₹39.00

Bansal Wire IPO Valuation – FY2023

Check Bansal Wire IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.

Earning Per Share (EPS):₹4.70 per Equity Share
Price/Earning P/E Ratio:N/A
Return on Net Worth (RoNW):21.21%
Net Asset Value (NAV):₹22.17 per Equity Share

Peer Group

  • Rajratan Global Wire Limited

Company Promoters

  • Arun Gupta
  • Anita Gupta,
  • Pranav Bansal
  • Arun Kumar Gupta HUF

Bansal Wire IPO Registrar

Kfin Technologies Limited
Phone: 04067162222, 04079611000
Email: bwil.ipo@kfintech.com
Website: https://kosmic.kfintech.com/ipostatus/

Bansal Wire IPO Allotment Status Check

Check Bansal Wire IPO allotment status on Kfin Technologies website allotment URL. Click Here

Bansal Wire IPO Lead Managers aka Merchant Bankers

  • SBI Capital Markets Limited
  • Dam Capital Advisors Ltd (Formerly Idfc Securities Ltd)

Company Address

Bansal Wire Industries Limited
F-3, Main Road
Shastri Nagar,
Delhi-110052
Phone: 011-2365 1891
Email: investorrelations@bansalwire.com
Website: https://bansalwire.com/

Bansal Wire IPO FAQs

What is Bansal Wire IPO?

Bansal Wire IPO is a main-board IPO. They are going to raise ₹745 Crores via IPO. The issue is priced at ₹243 to ₹256 pr equity share. The IPO is to be listed on BSE & NSE.

When Bansal Wire IPO will open?

The IPO is to open on July 3, 2024 for QIB, NII, and Retail Investors.

What is Bansal Wire IPO Investors Portion?

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

How to Apply the Bansal Wire IPO?

You can apply for Bansal Wire IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

How to Apply the Bansal Wire IPO through Zerodha?

Log in to Console in Zerodha Website or in Application. Go to Portfolio and Click on IPO. You will see the IPO Name “Bansal Wire”. Click on Bid Button. Enter your UPI ID, Quantity, and Price. Submit IPO Application Form. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate. Open Demat Account with Zerodha.

How to Apply the Bansal Wire IPO through Upstox?

Log in to the Upstox Application with your credentials. Select the IPO. You will see the IPO Name “Bansal Wire”. Click on Bid Button. Confirm your Application. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate. Open Demat Account with Upstox.

How to Apply the Bansal Wire IPO through Paytm Money?

Log in to Paytm Money Application with your credentials. Select the IPO. You will see the IPO Name “Bansal Wire”. Click on Bid Button. Confirm your Application. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate. Open Demat Account with Paytm Money.

What is Bansal Wire IPO Size?

Bansal Wire IPO size is ₹745 crores.

What is Bansal Wire IPO Price Band?

Bansal Wire IPO Price Band is ā‚¹243 to ₹256.

What is Bansal Wire IPO Minimum and Maximum Lot Size?

The minimum bid is 58 Shares with ₹14,848 amount while the maximum bid is 754 shares with ₹193,024.

What is the Bansal Wire IPO Allotment Date?

Bansal Wire IPO allotment date is July 8, 2024.

What is the Bansal Wire IPO Listing Date?

Bansal Wire IPO listing date is July 10, 2024. The IPO is to list on BSE and NSE.

Note: The Bansal Wire IPO price band and date are not officially announced yet. The IPO grey market premium (Bansal Wire IPO Premium) will be added to the IPO grey market page as it will start).

Table of Contents

Picture of Jagat Joshi

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.
Picture of Jagat Joshi

Jagat Joshi